Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry

Sui Shen, Sally J. DeNardo, Carol M Richman, Aina Yuan, Christine Hartmann Siantar, Robert T O'Donnell, Linda A. Kroger, Gerald L Denardo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Myelotoxicity can be ameliorated by peripheral blood stem cell (PBSC) infusion. Continuous irradiation by radioactivity retained in the body after high-dose radioimmunotherapy can damage PBSCs if they are transfused too early. Previously, infusion time was predetermined using the radioactivity concentration in the blood. This study proposes to plan PBSC infusion time based on noninvasive dosimetry that considers damage of PBSCs during PBSC circulation and residence in organs with high radioactivity. Methods: The method considers a time-varying distribution of PBSCs and radioactivity in tissues. Five breast cancer patients received 111In-2IT-BAD-m 170 for imaging, and 3 of the 5 received high doses of 09Y-2IT-BAD-m 170 therapy followed by PBSC infusion. 90Y concentrations in tissues were extrapolated from quantitative imaging of 111In, and 90Y blood concentrations were determined from 90Y in serial blood samples. The radiation dose to PBSCs was determined by time integration of the organ dose rate and PBSC distribution rate. The radiosensitivity of PBSCs was determined by measuring survival of granulocyte-macrophage colony-forming units with 90Y in cell culture. Results: The mean effective half-life of 90Y within the imaging period (up to 6 d) was 3.7 d for liver, 2.4 d for spleen, 2.1 d for kidneys, 1.8 d for lungs, and 1.6 d for blood. The survival fractions of PBSCs in patients were determined as functions of the infusion time and the injected dose of 90Y-2IT-BAD-m 170. To achieve 90% PBSC survival rate for a 2.0-GBq injection dose, PBSC dosimetry suggested a time interval of 13 d after radioimmunotherapy for PBSC infusion. In contrast, the simple blood concentration method suggested an interval about 7 d for the same PBSC survival rate. In our clinical practice, an interval of 2 wk has been used and worked well. Conclusion: A noninvasive dosimetry method was developed for optimizing the time interval for PBSC infusion after high-dose radionuclide therapy. Our studies suggested that the PBSC dosimetry method was more effective than the blood concentration method in determining the optimal time to reinfuse PBSCs for radiopharmaceuticals that have much a higher activity concentration in organs than that in the blood.

Original languageEnglish (US)
Pages (from-to)1034-1041
Number of pages8
JournalJournal of Nuclear Medicine
Volume46
Issue number6
StatePublished - 2005

Fingerprint

Radioisotopes
Radioactivity
Therapeutics
Radioimmunotherapy
Cell Survival
Peripheral Blood Stem Cells
Survival Rate
Granulocyte-Macrophage Progenitor Cells
Radiopharmaceuticals
Radiation Tolerance
Half-Life
Spleen
Cell Culture Techniques
Radiation
Breast Neoplasms
Kidney
Lung
Injections
Survival
Liver

Keywords

  • Bone marrow
  • Peripheral blood stem cell
  • Radiation dosimetry
  • Radioimmunotherapy
  • Treatment planning

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry. / Shen, Sui; DeNardo, Sally J.; Richman, Carol M; Yuan, Aina; Siantar, Christine Hartmann; O'Donnell, Robert T; Kroger, Linda A.; Denardo, Gerald L.

In: Journal of Nuclear Medicine, Vol. 46, No. 6, 2005, p. 1034-1041.

Research output: Contribution to journalArticle

Shen, Sui ; DeNardo, Sally J. ; Richman, Carol M ; Yuan, Aina ; Siantar, Christine Hartmann ; O'Donnell, Robert T ; Kroger, Linda A. ; Denardo, Gerald L. / Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry. In: Journal of Nuclear Medicine. 2005 ; Vol. 46, No. 6. pp. 1034-1041.
@article{d23670727e8f4dada6622e5f0d3bb0fb,
title = "Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry",
abstract = "Myelotoxicity can be ameliorated by peripheral blood stem cell (PBSC) infusion. Continuous irradiation by radioactivity retained in the body after high-dose radioimmunotherapy can damage PBSCs if they are transfused too early. Previously, infusion time was predetermined using the radioactivity concentration in the blood. This study proposes to plan PBSC infusion time based on noninvasive dosimetry that considers damage of PBSCs during PBSC circulation and residence in organs with high radioactivity. Methods: The method considers a time-varying distribution of PBSCs and radioactivity in tissues. Five breast cancer patients received 111In-2IT-BAD-m 170 for imaging, and 3 of the 5 received high doses of 09Y-2IT-BAD-m 170 therapy followed by PBSC infusion. 90Y concentrations in tissues were extrapolated from quantitative imaging of 111In, and 90Y blood concentrations were determined from 90Y in serial blood samples. The radiation dose to PBSCs was determined by time integration of the organ dose rate and PBSC distribution rate. The radiosensitivity of PBSCs was determined by measuring survival of granulocyte-macrophage colony-forming units with 90Y in cell culture. Results: The mean effective half-life of 90Y within the imaging period (up to 6 d) was 3.7 d for liver, 2.4 d for spleen, 2.1 d for kidneys, 1.8 d for lungs, and 1.6 d for blood. The survival fractions of PBSCs in patients were determined as functions of the infusion time and the injected dose of 90Y-2IT-BAD-m 170. To achieve 90{\%} PBSC survival rate for a 2.0-GBq injection dose, PBSC dosimetry suggested a time interval of 13 d after radioimmunotherapy for PBSC infusion. In contrast, the simple blood concentration method suggested an interval about 7 d for the same PBSC survival rate. In our clinical practice, an interval of 2 wk has been used and worked well. Conclusion: A noninvasive dosimetry method was developed for optimizing the time interval for PBSC infusion after high-dose radionuclide therapy. Our studies suggested that the PBSC dosimetry method was more effective than the blood concentration method in determining the optimal time to reinfuse PBSCs for radiopharmaceuticals that have much a higher activity concentration in organs than that in the blood.",
keywords = "Bone marrow, Peripheral blood stem cell, Radiation dosimetry, Radioimmunotherapy, Treatment planning",
author = "Sui Shen and DeNardo, {Sally J.} and Richman, {Carol M} and Aina Yuan and Siantar, {Christine Hartmann} and O'Donnell, {Robert T} and Kroger, {Linda A.} and Denardo, {Gerald L}",
year = "2005",
language = "English (US)",
volume = "46",
pages = "1034--1041",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "6",

}

TY - JOUR

T1 - Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry

AU - Shen, Sui

AU - DeNardo, Sally J.

AU - Richman, Carol M

AU - Yuan, Aina

AU - Siantar, Christine Hartmann

AU - O'Donnell, Robert T

AU - Kroger, Linda A.

AU - Denardo, Gerald L

PY - 2005

Y1 - 2005

N2 - Myelotoxicity can be ameliorated by peripheral blood stem cell (PBSC) infusion. Continuous irradiation by radioactivity retained in the body after high-dose radioimmunotherapy can damage PBSCs if they are transfused too early. Previously, infusion time was predetermined using the radioactivity concentration in the blood. This study proposes to plan PBSC infusion time based on noninvasive dosimetry that considers damage of PBSCs during PBSC circulation and residence in organs with high radioactivity. Methods: The method considers a time-varying distribution of PBSCs and radioactivity in tissues. Five breast cancer patients received 111In-2IT-BAD-m 170 for imaging, and 3 of the 5 received high doses of 09Y-2IT-BAD-m 170 therapy followed by PBSC infusion. 90Y concentrations in tissues were extrapolated from quantitative imaging of 111In, and 90Y blood concentrations were determined from 90Y in serial blood samples. The radiation dose to PBSCs was determined by time integration of the organ dose rate and PBSC distribution rate. The radiosensitivity of PBSCs was determined by measuring survival of granulocyte-macrophage colony-forming units with 90Y in cell culture. Results: The mean effective half-life of 90Y within the imaging period (up to 6 d) was 3.7 d for liver, 2.4 d for spleen, 2.1 d for kidneys, 1.8 d for lungs, and 1.6 d for blood. The survival fractions of PBSCs in patients were determined as functions of the infusion time and the injected dose of 90Y-2IT-BAD-m 170. To achieve 90% PBSC survival rate for a 2.0-GBq injection dose, PBSC dosimetry suggested a time interval of 13 d after radioimmunotherapy for PBSC infusion. In contrast, the simple blood concentration method suggested an interval about 7 d for the same PBSC survival rate. In our clinical practice, an interval of 2 wk has been used and worked well. Conclusion: A noninvasive dosimetry method was developed for optimizing the time interval for PBSC infusion after high-dose radionuclide therapy. Our studies suggested that the PBSC dosimetry method was more effective than the blood concentration method in determining the optimal time to reinfuse PBSCs for radiopharmaceuticals that have much a higher activity concentration in organs than that in the blood.

AB - Myelotoxicity can be ameliorated by peripheral blood stem cell (PBSC) infusion. Continuous irradiation by radioactivity retained in the body after high-dose radioimmunotherapy can damage PBSCs if they are transfused too early. Previously, infusion time was predetermined using the radioactivity concentration in the blood. This study proposes to plan PBSC infusion time based on noninvasive dosimetry that considers damage of PBSCs during PBSC circulation and residence in organs with high radioactivity. Methods: The method considers a time-varying distribution of PBSCs and radioactivity in tissues. Five breast cancer patients received 111In-2IT-BAD-m 170 for imaging, and 3 of the 5 received high doses of 09Y-2IT-BAD-m 170 therapy followed by PBSC infusion. 90Y concentrations in tissues were extrapolated from quantitative imaging of 111In, and 90Y blood concentrations were determined from 90Y in serial blood samples. The radiation dose to PBSCs was determined by time integration of the organ dose rate and PBSC distribution rate. The radiosensitivity of PBSCs was determined by measuring survival of granulocyte-macrophage colony-forming units with 90Y in cell culture. Results: The mean effective half-life of 90Y within the imaging period (up to 6 d) was 3.7 d for liver, 2.4 d for spleen, 2.1 d for kidneys, 1.8 d for lungs, and 1.6 d for blood. The survival fractions of PBSCs in patients were determined as functions of the infusion time and the injected dose of 90Y-2IT-BAD-m 170. To achieve 90% PBSC survival rate for a 2.0-GBq injection dose, PBSC dosimetry suggested a time interval of 13 d after radioimmunotherapy for PBSC infusion. In contrast, the simple blood concentration method suggested an interval about 7 d for the same PBSC survival rate. In our clinical practice, an interval of 2 wk has been used and worked well. Conclusion: A noninvasive dosimetry method was developed for optimizing the time interval for PBSC infusion after high-dose radionuclide therapy. Our studies suggested that the PBSC dosimetry method was more effective than the blood concentration method in determining the optimal time to reinfuse PBSCs for radiopharmaceuticals that have much a higher activity concentration in organs than that in the blood.

KW - Bone marrow

KW - Peripheral blood stem cell

KW - Radiation dosimetry

KW - Radioimmunotherapy

KW - Treatment planning

UR - http://www.scopus.com/inward/record.url?scp=23044501951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044501951&partnerID=8YFLogxK

M3 - Article

C2 - 15937317

AN - SCOPUS:23044501951

VL - 46

SP - 1034

EP - 1041

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -